AFM
IMUX icon

Anson Funds Management’s Immunic IMUX Stock Holding History

Anson Funds Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-66,494
Closed -$931K – 196
2022
Q4 		$931K Buy
+66,494
New +$1.81M 0.15% 113
2017
Q1 		– Sell
-155
Closed -$270K – 65
2016
Q4 		$270K Buy
+155
New +$339K 0.08% 64

Other funds holding IMUX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Anson Funds Management's IMUX Position: Q1 2023 in Review

Anson Funds Management sold out of Immunic (IMUX) in Q1 2023, closing a stake of 66,494 shares — an estimated $931K sold.

Anson Funds Management first reported a position in IMUX in Q4 2016 and held it in 2 quarters. The position peaked at $931K in Q4 2022. 59 funds tracked by Wall St. Rank hold IMUX as of Q1 2023.

  • Anson Funds Management reported no remaining Immunic position as of Q1 2023 after selling out during the quarter.
  • Anson Funds Management sold 66,494 Immunic shares in Q1 2023, an estimated $931K.
  • Anson Funds Management first reported a position in Immunic in Q4 2016 and held it in 2 quarters.
  • Anson Funds Management's Immunic position peaked at $931K in Q4 2022.
  • 59 funds tracked by Wall St. Rank held Immunic as of Q1 2023.

Based on Anson Funds Management's 13F filing for Q1 2023, filed 15 May 2023.